Cipla obtains FDA permission for generic Durezol
Durezol had a market value of roughly $106 million for the 12-month period ended June 2021, according to IQVIA data.
Cipla has received the Food and Drug Administration’s blessing for difluprednate ophthalmic emulsion 0.05%.
Cipla's product is the generic of Novartis’ Durezol.
The medication is used for the treatment of inflammation and pain associated with ocular surgery, and endogenous anterior uveitis.
Durezol had a market value of approximately $106 million for the 12-month period ended June 2021, according to IQVIA data.
Cipla said that the product will be available for shipping soon.